CYCLACEL PHARMACEUTICALS INC (CYCC) Stock News

USA - Nasdaq - NASDAQ:CYCC - US23254L8019 - Common Stock

6.365 USD

-0.4 (-5.98%)

Last: 9/11/2025, 8:00:01 PM

6.4 USD

+0.04 (+0.55%)

After Hours: 9/11/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CYCC Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: Bio Green Med Solution, Inc. - Mentions: BGMS

Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.

3 months ago - By: Bio Green Med Solution, Inc. - Mentions: BGMS

Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.

4 months ago - By: Benzinga

How Is The Market Feeling About Cyclacel Pharmaceuticals?

4 months ago - By: Cyclacel

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

4 months ago - By: Cyclacel

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

4 months ago - By: Benzinga - Mentions: BTBD PLTR OPAD AIP ...

Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

4 months ago - By: Cyclacel Pharmaceuticals, Inc.

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

5 months ago - By: Cyclacel Pharmaceuticals, Inc.

CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY

5 months ago - By: Cyclacel Pharmaceuticals, Inc.

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

5 months ago - By: Cyclacel Pharmaceuticals, Inc.

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

5 months ago - By: Yahoo Finance - Mentions: VZ

Cyclacel Pharmaceuticals announces 1-for-15 reverse stock split